Vimarsana
Biggest News Aggregation in the World

Page 10 - Communicative Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Communicative Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Communicative Disorders Today - Breaking & Trending Today

India Ignited: COVID-19 Second Wave Unleashes Death and Devastation - Vimarsana News

India Ignited: COVID-19 Second Wave Unleashes Death and Devastation

India Ignited: COVID-19 Second Wave Unleashes Death and Devastation | Opinion Soma Sen, Tanvi Kothari and Nidhi Mahendra On 5/6/21 at 8:00 AM EDT COVID-19 recently took a fierce aim in India, turning it into the latest gruesome epicenter of the global coronavirus pandemic. As Indian American professors at San José State University, who have given the best of ourselves to the United States, we implore you to take seriously what is happening in India. Our Indian American personas and Indian hearts reel in shock, eyes sting with tears and our feelings lie in tatters as we bea...

SJSU's Inaugural Public Voices Fellows | Office of the Provost - Vimarsana News

SJSU's Inaugural Public Voices Fellows | Office of the Provost

SJSU’s Inaugural Public Voices Fellows A group of 22 faculty members have made SJSU history as the inaugural cohort of the Public Voices Fellows program. Public Voices is an exciting new professional development opportunity launched by the Office of the Provost, the Center for Faculty Development, and the OpEd Project, which aims to amplify expert voices that have been underrepresented in efforts to address today’s most pressing issues. Fellows learned what makes an idea contagious in the public sphe...

Source: sjsu.edu
A USU student has started a children's series and hopes to inspire others with his stories - Vimarsana News

A USU student has started a children's series and hopes to inspire others with his stories

on January 27, 2021 at 12:18 am A Boy and His Elephant is the first in a new series of children’s books written by Ethan Watson, a Cache Valley native and Utah State University student. The book aims to answer some of life’s greatest questions in the most simple and sincere ways.  During the summer of 2020, Watson realized that his calendar was looking fairly empty. This freed up time, due to COVID-19, allowed him to explore and prompted the idea for A Boy and His Elephant.  Watson believes that during the uncertainty of COVID-19, there are difficult questions that need to be addressed...

Black Inspirations of 2020 - Los Angeles Sentinel - Vimarsana News

Black Inspirations of 2020 - Los Angeles Sentinel

Black Inspirations of 2020 Published December 31, 2020 Ernestine Johnson Morrison Actress and entrepreneur, Ernestine Johnson Morrison founded several businesses including Green Lit ATL and The Legacy Center. Green Lit ATL is the premiere film industry event where creators are able to show off their work and network amongst the industry. The Legacy Center, also known as “The Blackhouse” is a co-working and educational center to help broaden the horizon for young Black entrepreneurs and elevate their businesses. She, along with her husband, Jay Morrison, also founded the Tulsa Real Estate ...

AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer's disease met its primary endpoint - Vimarsana News

AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer's disease met its primary endpoint

Share: PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER'S DISEASE MET ITS PRIMARY ENDPOINT MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS Paris, December 16, 2020, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer's disease met its pr...